124 related articles for article (PubMed ID: 3738864)
1. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model.
Walenga JM; Fareed J; Petitou M; Samama M; Lormeau JC; Choay J
Thromb Res; 1986 Jul; 43(2):243-8. PubMed ID: 3738864
[No Abstract] [Full Text] [Related]
2. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
Walenga JM; Bara L; Petitou M; Samama M; Fareed J; Choay J
Thromb Res; 1988 Jul; 51(1):23-33. PubMed ID: 3166242
[TBL] [Abstract][Full Text] [Related]
4. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
Walenga JM; Fareed J
Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
[No Abstract] [Full Text] [Related]
5. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments.
Racanelli A; Fareed J; Walenga JM; Coyne E
Semin Thromb Hemost; 1985 Apr; 11(2):176-89. PubMed ID: 4035365
[No Abstract] [Full Text] [Related]
6. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
7. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
[TBL] [Abstract][Full Text] [Related]
8. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
Fareed J; Kumar A; Rock A; Walenga JM; Davis P
Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
Hollenbach S; Sinha U; Lin PH; Needham K; Frey L; Hancock T; Wong A; Wolf D
Thromb Haemost; 1994 Mar; 71(3):357-62. PubMed ID: 8029801
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Vogel GM; Lormeau JC; Petitou M; Meuleman DG
Circ Res; 1996 Sep; 79(3):590-600. PubMed ID: 8781492
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Lormeau JC; Petitou M; van Boeckel C; Hoffmann P; Meuleman DG
Blood; 1998 Jun; 91(11):4197-205. PubMed ID: 9596667
[TBL] [Abstract][Full Text] [Related]
12. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
[TBL] [Abstract][Full Text] [Related]
13. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
Thomas DP; Merton RE; Gray E; Barrowcliffe TW
Thromb Haemost; 1989 Apr; 61(2):204-7. PubMed ID: 2546282
[TBL] [Abstract][Full Text] [Related]
14. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides.
Barrowcliffe TW; Merton RE; Havercroft SJ; Thunberg L; Lindahl U; Thomas DP
Thromb Res; 1984 Apr; 34(2):125-33. PubMed ID: 6729774
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
Bara L; Trillou M; Mardiguian J; Samama M
Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
[TBL] [Abstract][Full Text] [Related]
16. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
[TBL] [Abstract][Full Text] [Related]
17. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.
Choay J
Semin Thromb Hemost; 1985 Apr; 11(2):81-5. PubMed ID: 4035368
[TBL] [Abstract][Full Text] [Related]
18. Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction.
Ockelford PA; Carter CJ; Mitchell L; Hirsh J
Thromb Res; 1982 Nov; 28(3):401-9. PubMed ID: 7179224
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
[TBL] [Abstract][Full Text] [Related]
20. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
Thomas DP; Merton RE; Barrowcliffe TW
Ann N Y Acad Sci; 1989; 556():313-22. PubMed ID: 2735662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
